{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:47:55Z","timestamp":1792277275421,"version":"4.4.0"},"reference-count":12,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2022.2527","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T09:56:12Z","timestamp":1646128572000},"source":"Crossref","is-referenced-by-count":9,"title":["Regression of advanced maxillary sinus cancer with orbital invasion by combined chemotherapy and immunotherapy: A one\u2011year follow\u2011up case report"],"prefix":"10.3892","volume":"16","author":[{"given":"Yu-Hsuan","family":"Kuo","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Chi\u2011Mei Medical Center, Tainan 710, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Shin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Chi\u2011Mei Medical Center, Tainan 710, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"issue":"e36","key":"key20220330115643_b1-MCO-16-4-02527","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2009.e36","article-title":"Treatment outcome of maxillary sinus cancer","volume":"1","author":"Won","year":"2009","journal-title":"Rare Tumours"},{"issue":"e2614","key":"key20220330115643_b2-MCO-16-4-02527","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2614","article-title":"Carcinoma of the maxillary antrum: A case report","volume":"10","author":"Praveena","year":"2018","journal-title":"Cureus"},{"key":"key20220330115643_b3-MCO-16-4-02527","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1002\/1097-0142(20011215)92:12<3012::aid-cncr10131>3.0.co;2-e","article-title":"Nasal and paranasal sinus carcinoma: Are we making progress? A series of 220 patients and a systematic review","volume":"92","author":"Dulguerov","year":"2001","journal-title":"Cancer"},{"key":"key20220330115643_b4-MCO-16-4-02527","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/MOO.0000000000000138","article-title":"Management of the neck in maxillary sinus carcinomas","volume":"23","author":"Dooley","year":"2015","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"key20220330115643_b5-MCO-16-4-02527","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4021\/wjon2010.02.191w","article-title":"Results of treatment of squamous cell carcinoma of maxillary sinus: A 26-year experience","volume":"1","author":"Ashraf","year":"2010","journal-title":"World J Oncol"},{"issue":"487872","key":"key20220330115643_b6-MCO-16-4-02527","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/487872","article-title":"Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus","volume":"2014","author":"Noronha","year":"2014","journal-title":"Chemother Res Pract"},{"key":"key20220330115643_b7-MCO-16-4-02527","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/lary.28042","article-title":"Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report","volume":"130","author":"Xiang","year":"2020","journal-title":"Laryngoscope"},{"issue":"e3519","key":"key20220330115643_b8-MCO-16-4-02527","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3519","article-title":"The synergistic effect of immune checkpoint blockade and radiotherapy in recurrent\/metastatic sinonasal cancer","volume":"10","author":"Yazici","year":"2018","journal-title":"Cureus"},{"issue":"435","key":"key20220330115643_b9-MCO-16-4-02527","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00435","article-title":"Radiation therapy combined with checkpoint blockade immunotherapy for metastatic undifferentiated pleomorphic sarcoma of the maxillary sinus with a complete response","volume":"8","author":"Guram","year":"2018","journal-title":"Front Oncol"},{"key":"key20220330115643_b10-MCO-16-4-02527","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20220330115643_b11-MCO-16-4-02527","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"key20220330115643_b12-MCO-16-4-02527","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: Harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T08:58:20Z","timestamp":1648630700000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2022.2527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2022.2527","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"94"}}